In rheumatoid arthritis (RA), bone and cartilage are invaded and destroyed by fibroblastic cells, resulting in crippling joint disease. In other systemic inflammatory diseases, such as lupus and scleroderma, fibrotic scar tissue can develop in organs, such as the lungs or kidneys, leading to severe disability or death. These diverse pathologic processes have in common the prominent involvement of fibroblasts. Although fibroblasts are normally resting cells which help maintain tissue integrity, following injury they become activated to proliferate and produce extracellular matrix in order to promote wound healing. In fibrotic processes and in RA, these normal functions have gone destructively awry. It is unclear from studies to date whether all fibroblasts participate equally in these events. We and others have described a subset of normal fibroblasts in rats and mice, characterized by the absence of the surface glycoprotein Thy- l, which share many phenotypic features of the activated fibroblasts seen in fibrosis and RA. The human equivalent of Thy-1, CD90, is also expressed on only a portion of normal fibroblasts, but the characteristic features of CD90 subpopulations have not been described. We predict that Thy-1/CD90- and Thy-1/CD90+ fibroblasts have distinct roles in tissue remodeling, and that Thy-1/CD90 expression is altered in the progression of fibrotic and arthritic lesions. Accordingly, the specific aims of the proposed investigation will be: l) To measure CD90 expression in fibroblasts derived from involved tissues in connective tissue diseases and arthritic synovium, by comparing CD90 expression in fibroblasts from fibrogenic lesions and arthritic synovium vs. normal tissues; 2) To define the differential biology of human CD9O fibroblast subpopulations, by comparing differential gene expression patterns in sorted Thy-1-/+ and CD90-/+ fibroblasts; and 3) To characterize the """"""""matrix-invasive"""""""" phenotype of CD90 fibroblast subpopulations, by measuring the migratory and invasive activity of Thy- 1/CD90-/+ fibroblasts. Information derived from these studies will add a new dimension to the current understanding of molecular mechanisms of fibroblast activation in these crippling conditions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Comprehensive Center (P60)
Project #
5P60AR020614-24
Application #
6413212
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Project Start
2001-01-01
Project End
2002-12-31
Budget Start
Budget End
Support Year
24
Fiscal Year
2001
Total Cost
$116,317
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Wu, Jianming; Xie, Fenglong; Qian, Kun et al. (2011) FAS mRNA editing in Human Systemic Lupus Erythematosus. Hum Mutat 32:1268-77
Wang, Feng; Ezell, Scharri J; Zhang, Yong et al. (2010) FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs 28:234-41
Wang, Wei; Rayburn, Elizabeth R; Velu, Sadanandan E et al. (2009) In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res 15:3511-8
Wang, Wei; Rayburn, Elizabeth R; Zhao, Yuqing et al. (2009) Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett 278:241-248
Wang, Wei; Rayburn, Elizabeth R; Hang, Jie et al. (2009) Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer 65:306-11
Wang, Wei; Rayburn, Elizabeth R; Hao, Miao et al. (2008) Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 68:809-19
Annis, Douglas S; Gunderson, Kristin A; Mosher, Deane F (2007) Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations. J Biol Chem 282:27067-75
Rayburn, Elizabeth R; Wang, Wei; Zhang, Ruiwen et al. (2007) Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 30:1511-9
Wang, Hui; Rayburn, Elizabeth R; Wang, Wei et al. (2006) Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther 5:2106-14
Annis, D S; Murphy-Ullrich, J E; Mosher, D F (2006) Function-blocking antithrombospondin-1 monoclonal antibodies. J Thromb Haemost 4:459-68

Showing the most recent 10 out of 145 publications